@prefix orcid: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix rdf: .
@prefix xsd: .
@prefix rdfs: .
@prefix ns2: .
@prefix ns1: .
@prefix prov: .
@prefix ns3: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubInfo;
a np:Nanopublication .
}
sub:assertion {
ns1:demonstrate .
}
sub:provenance {
sub:assertion prov:generatedAtTime "2021-12-16T19:48:33.752951"^^xsd:dateTime;
prov:wasGeneratedBy "S&T TWOC project version 2" .
sub:version prov:value "2"^^xsd:integer .
rdf:OBJECT rdfs:label "clinical efficacythrough randomized controlled trials ( RCTs ) in seriously ill patients" .
rdf:OBJECT-POSITION rdfs:label "79"^^xsd:integer .
rdf:PREDICATE rdfs:label "demonstrated" .
rdf:PREDICATE-POSITION rdfs:label "[65]" .
rdf:SUBJECT rdfs:label "only two treatments , remdesivir and dexamethasone" .
rdf:SUBJECT-POSITION rdfs:label "36"^^xsd:integer .
rdfs:ABSTRACT-UID ns2:50 "gvu30egy" .
rdfs:SENTENCE rdfs:label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." .
rdfs:TRIPLE-UID ns3:gvu30egy-TRIPLE-ABSTRACT-1 "gvu30egy-TRIPLE-ABSTRACT-1" .
rdfs:label "dexamethasone" .
rdfs:label "patients" .
}
sub:pubInfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB";
npx:hasSignature "cVOk/E/z+VG8UMAsfz1vZ3BpxA/tmK6yydYPNfXfQFAIXIGlep8h1J4Fnmu8OY/wv3eEA2cHtASjI08K8rRsnxZs75XK8TuZii3MpnDAHB3E+oPDuwCg9FPR+vOys3WJFdXnOaKWfsB1nXC19pAVhO0dGTnCT8U+zgd4HqOyncg=";
npx:hasSignatureTarget this: .
this: prov:generatedAtTime "2021-12-16T19:48:33.752951"^^xsd:dateTime;
prov:wasAttributedTo orcid:0000-0002-8954-0470 .
}